Sildenafil induces powerful cardioprotection against ischemia/reperfusion (I/R) injury. Since adenosine is known to be a major trigger of ischemic preconditioning, we hypothesized that A 1 adenosine receptor (A 1 AR) activation plays a role in sildenafil-induced cardioprotective signaling. Adult male C57BL wild-type (WT) mice or their corresponding A 1 AR knockout (A 1 AR-KO) mice were treated intraperitoneally (i.p.) with either sildenafil (0.71 mg/kg, equivalent to 50 mg dose for a 70 kg patient) or volume-matched saline. The selective A 1 AR antagonist 8-cyclopentyl-1,3-dipropyxanthine (DPCPX; 0.1 mg/kg, i.p.) was administered 30 min before sildenafil. The hearts were isolated 24 h later and subjected to 30 min of global ischemia and 1 h of reperfusion in Langendorff mode. Post-ischemic myocardial infarct size (mean ± SEM; % of risk area) was reduced in C57BL-WT mice treated with sildenafil (5.6 ± 0.9) versus saline control group (27.3 ± 2.1; p b 0.05; n = 6/each). However, sildenafil failed to protect the A 1 AR-KO hearts (31.6 ± 1.9 vs. 32.3 ± 1.5 with saline, p N 0.05). Additionally, DPCPX treatment abolished the infarct limiting effect of sildenafil (27.3 ± 3.2, p b 0.05). DPCPX alone had no effect on infarct size as compared with the control group. No significant changes in post-ischemic recovery of left ventricular pressure and heart rate were observed in the sildenafil-treated group. We further examined the effect of sildenafil in protection against simulated ischemia and reoxygenation injury in adult cardiomyocytes derived from WT and A 1 AR-KO mice. WT myocytes treated with sildenafil (1 μM) demonstrated significantly lower trypan blue-positive necrotic cells. However, cardiomyocytes derived from A 1 AR-KO mice or DPCPX-treated WT cells failed to show protection against necrosis with sildenafil. These results suggest that A 1 AR activation following treatment with sildenafil plays an integral role in the signaling cascade responsible for delayed protection against global I/R injury.
Introduction
Phosphodiesterase-5 (PDE-5) inhibitors including sildenafil, vardenafil and tadalafil are a class of drugs that have been developed for treatment of erectile dysfunction (ED) [1] and more recently for pulmonary artery hypertension [2] . We first showed that sildenafil induced preconditioning-like protective effects against ischemia/reperfusion (I/R) injury in the rabbit [3] and mouse heart [4] . Moreover, sildenafil attenuated necrosis as well as apoptosis in adult cardiomyocytes subjected to simulated ischemia/reoxygenation (SI/RO) [5] . A series of studies from our laboratory further showed that activation of protein kinase C [6] , phosphorylation of extracellular-signalregulated kinase (ERK) [7] , synthesis of inducible and endothelial nitric oxide synthases (iNOS/eNOS) [4] and opening of mitochondrial K ATP channels [3] played a crucial role in protection against I/R injury with sildenafil. More recently, we also showed that both sildenafil and vardenafil provided cardioprotection against I/R through opening of mitochondrial K ATP channels when these drugs were infused at the time of reperfusion in rabbits [8] .
Adenosine has been shown to be an important mediator of acute and delayed cardiac preconditioning [9] [10] [11] . Adenosine receptor activation has been shown to protect the heart against Available online at www.sciencedirect.com www.elsevier.com/locate/yjmcc reversible and irreversible ischemic injury in multiple species and preparations [12, 13] . Moreover, A 1 AR knockout (A 1 AR-KO) mice completely abolished the cardioprotective effect of ischemic preconditioning [14] . Previous studies from our laboratory have also shown that A 1 AR activation induces delayed protection through induction of iNOS [15] and opening of K ATP channel [11] . Considering several similarities between the signaling cascade triggered by A 1 AR activation and sildenafil-induced protection, we hypothesized that the infarct limiting effect of sildenafil might be mediated via activation of A 1 AR. We speculated that sildenafil pretreatment would mimic a delayed preconditioning-like effect potentially through increased A 1 AR expression or augmented adenosine release from cells into the interstitial fluid which would make adenosine available to interact with its receptors, particularly during ischemia. In the current investigation, we took advantage of the A 1 AR-KO mice and the selective A 1 AR antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) to elucidate the direct cause-and-effect of A 1 AR in inducing delayed cardioprotection in mice following treatment with sildenafil.
Materials and methods

Animals
Adult male C57BL mice were supplied by The Jackson Laboratory (Bar Harbor, ME). The body weight for these animals ranged between 27.1 and 32.7 g. A 1 AR-KO mice were obtained from a sub-colony of the original lines generated by Sun et al. [16] . A 1 AR-KO mice were bred on site at the Virginia Commonwealth University School of Medicine. The deletion of A 1 AR gene in the knockout mice was confirmed by RT-PCR.
Langendorff isolated perfused heart preparation
The methodology of the Langendorff isolated perfused heart has been previously described in detail [17] . In brief, the mice were anesthetized with an i.p. injection of sodium pentobarbital (100 mg/kg containing 33 international units of heparin). The hearts were removed and submerged in ice-cold KrebsHenseleit (K-H) solution containing heparin. The aorta was secured to a 20 gauge stainless steel blunt needle, and the hearts were perfused at a constant temperature and pressure in a retrograde fashion via the aorta with K-H solution. Following a stabilization period of 30 min, I/R injury was produced by subjecting the hearts to 30 min of normothermic, no-flow global ischemia followed by reperfusion for 60 min. To obtain the developed pressure, a left atrial incision was made to expose the mitral annulas through which a water-filled latex balloon was passed into the left ventricle (LV). The balloon was attached via polyethylene tubing to a Gould pressure transducer that was connected to a PowerLab Acquisition System (ADInstruments 8SP, Australia). The balloon was inflated to adjust the LV enddiastolic pressure (LVEDP) to ∼ 10 mm Hg. Myocardial ischemic damage was measured using multiple, independent end points of tissue injury. These included infarct size, LV developed pressure (LVDP), LVEDP, rate pressure product (RPP), heart rate, and coronary flow by timed collection of the perfusate. LVDP was calculated by subtracting LVEDP from the peak systolic pressure. RPP, an index of cardiac work, was calculated by multiplying LVDP with heart rate. The hearts were not paced.
Study protocol
Mice were randomly assigned into one of the following groups as shown in Fig. 1 :
Group I (saline control, C57BL (WT) mice; n = 6): WT mice received 0.2 ml 0.9% saline, i.p.; Group II (sildenafil, WT mice; n = 6): Pure sildenafil powder (kindly provided by Pfizer, Inc.) was dissolved in 0.2 ml saline. This preparation was given in WT mice as 0.71 mg/kg i.p. bolus, approximating, on a mg/kg basis, the clinical dose of 50 mg administered to a 70 kg patient; Group III (DPCPX + sildenafil, WT mice; n = 6): DPCPX (0.1 mg/kg) was administered 30 min prior to sildenafil treatment in WT mice as in Group II; Group IV (DPCPX + saline, WT mice; n = 6): WT mice were treated with DPCPX (0.1 mg/kg) 30 min prior to saline treatment as in Group I; Group V (DMSO + sildenafil, WT mice, n = 6): DMSO (solvent for DPCPX) was administered in WT mice 30 min prior to sildenafil treatment as in group II; Group VI (DMSO + saline, WT mice, n = 6): WT mice were given DMSO 30 min prior to saline treatment as in Group I; Group VII (saline control, A 1 AR-KO; n = 6): A 1 AR-KO mice received 0.2 ml 0.9% saline, i.p.; Group VIII (sildenafil, A 1 AR-KO; n = 6): A 1 AR-KO mice received 0.71 mg/kg sildenafil as in Group II.
Twenty-four hours later, the hearts were isolated and subjected to I/R as described above.
Isolation of adult mouse ventricular cardiomyocytes
Adult male C57BL-WT or A 1 AR-KO mice were used in this study. The ventricular cardiomyocytes were isolated using an enzymatic technique modified from the previously reported method [5, 18, 19] . In brief, the animal was anesthetized with pentobarbital sodium (100 mg/kg, i.p.) and the heart was quickly removed. Within 3 min, the aortic opening was cannulated onto a Langendorff perfusion system and the heart was retrogradely perfused (37°C) at a constant pressure of 55 mm Hg for ∼5 min with a Ca 2+ -free bicarbonate-based buffer containing (in mM): 120 NaCl, 5.4 KCl, 1.2 MgSO 4 , 1.2 NaH 2 PO 4 , 5.6 glucose, 20 NaHCO 3 , 10 2,3-butanedione monoxime, and 5 taurine, which was continuously bubbled with 95%O 2 + 5%CO 2 . The enzymatic digestion was commenced by adding collagenase type II (Worthington, 0.5 mg/ml each) and protease type XIV (0.02 mg/ml) to the perfusion buffer and continued for ∼15 min. 50 μM Ca 2+ was then added in to the enzyme solution for perfusing the heart for another 10-15 min. The digested ventricular tissue was cut into chunks and gently aspirated with a transfer pipette for facilitating the cell dissociation. The cell pellet was resuspended for a 3-step Ca 2+ restoration procedure (i.e., 125, 250, 500 μM Ca 2+ ). The freshly isolated cardiomyocytes were then suspended in minimal essential medium (Sigma catalogue# 6 M1018, pH 7.35-7.45) containing 1.2 mM Ca 2+ , 12 mM NaHCO 3 , 2.5% fetal bovine serum, and 1% penicillin-streptomycin. The cells were then plated onto the 35 mm cell culture dishes, which were precoated with 20 μg/ml mouse laminin in PBS + 1% penicillinstreptomycin for 1 h. The cardiomyocytes were cultured in the presence of 5% CO 2 for 1 h in a humidified incubator at 37°C, which allowed cardiomyocytes to attach to the dish surface prior to the experimental protocol.
Experimental protocol
The cultured cardiomyocytes were incubated under 37°C and 5% CO 2 for 1 h with or without 1 μM sildenafil powder dissolved in distilled water. The drug solution was filtered (0.45 μm pore size) before adding into the cell medium. Cardiomyocytes were subjected to simulated ischemia (SI) for 40 min by replacing the cell medium with an "ischemia buffer" which contained (in mM): 118 NaCl, 24 NaHCO 3 , 1.0 NaH 2 PO 4 , 2.5 CaCl 2 -2H 2 O, 1.2 MgCl 2 , 20 sodium lactate, 16 KCl, 10 2-deoxyglucose (pH adjusted to 6.2). In addition, the cells were incubated under hypoxic conditions at 37°C during the entire SI period by adjusting the tri-gas incubator to 1-2% O 2 and 5% CO 2 . Reoxygenation (RO) was accomplished by replacing the ischemic buffer with normal medium under normoxic conditions. Assessment of cell necrosis was performed after 1 h of RO.
Evaluation of cell viability
Cell viability was assessed by trypan blue exclusion assay. At the end of protocol, 20 μL of 0.4% trypan blue (Sigma-Aldrich) was added into the culture dish. After ∼5 min of equilibration, the cells were counted under microscope. 
Statistics
All measurements are expressed as means ± SE. The data were analyzed by either unpaired t-test or one-way ANOVA. If a significant value of F was obtained in ANOVA, the StudentNewman-Keuls post hoc test was further used for pairwise comparisons. Paired t-test was used to compare any pair of preand post-treatment values for the same parameter. p b 0.05 was considered significant.
Results
Left ventricular cardiac function
There was no significant difference in the basal functional parameters (i.e., heart rate, LVDP, and LVEDP) between the groups after 20 min of stabilization (Table 1) . Except in the A 1 AR-KO mice treated with saline, no significant changes in the rate pressure product were observed during post-ischemia (Fig. 2) between the groups. Post-ischemic coronary flow was also not significantly different among the groups as shown in Table 2 .
Myocardial infarction
Following I/R, myocardial infarct size (mean ± SEM; % of risk area) was reduced in wild-type mice treated with sildenafil (5.6 ± 0.9) versus saline group (27.3 ± 2.1; p b 0.05; n = 6/each; Fig. 3 ). In contrast, sildenafil failed to reduce infarct size in the A 1 AR-KO mice (31.6 ± 1.9 vs. 32.3 ± 1.5 with saline, p N 0.05).
Moreover, the selective A 1 AR antagonist DPCPX blocked the infarct-limiting effect of sildenafil in the wild-type mice (27.3 ± 3.2, p b 0.05). There was no significant difference in the infarct size between controls and animals treated with DPCPX or DMSO, the solvent for DPCPX.
Effect of sildenafil on cardiomyocyte necrosis
Our method for cell preparations yielded at least 70% of the cardiomyocytes with rod shape morphology, which was similar to the previously reported study from our laboratory and others [5, 18, 19] . After 40 min of SI and 1 h of RO, the percent of trypan blue-positive cardiomyocytes was 53 ± 2.8 (control). Pretreatment with sildenafil for 1 h resulted in the ∼ 54% decrease in trypan blue-positive cardiomyocytes (i.e., 24.5 ± 2.6% p b 0.05, vs. control n = 3; Fig. 4 ). The A 1 AR selective antagonist, DPCPX, abolished the protective effect of sildenafil as shown by the increase in the trypan blue-positive cells (50.8 ± 3.0; p N 0.05 vs. control). DPCPX or its solvent DMSO alone had no effect on trypan blue-positive cell count. Furthermore, cardiomyocytes derived from A 1 AR-KO mice failed to show protection against SI/RO when treated with sildenafil (46.7 ± 2.3% vs. 51.9 ± 4.4 non-treated control A 1 AR-KO cardiomyocytes; p N 0.05).
Discussion
The major goal of this study was to test the hypothesis whether A 1 AR plays an obligatory role in protection against I/R injury with sildenafil in the intact heart and cardiomyocytes. As previously shown in the ICR mice also [4] , sildenafil caused an impressive reduction of infarct size in hearts isolated from C57BL-WT mice. The protection was abolished by both selective A 1 AR antagonist DPCPX as well as genetic deletion of A 1 AR. Similar results were obtained in an independent acute model of primary adult murine cardiomyocytes that were subjected to SI/RO in vitro. The number of trypan blue-positive necrotic cells following SI/RO was significantly lower in the sildenafil-treated group as compared with the saline-treated control cardiomyocytes. Also, sildenafil-induced protection against SI/RO was abolished by DPCPX in the wild-type cardiomyocytes or in cardiomyocytes isolated from A 1 AR-KO Fig. 2 . Effect of sildenafil, DPCPX, and genetic deletion of A 1 AR on ventricular functional recovery following global ischemia-reperfusion. Table 2 Pre-ischemia and reperfusion coronary flow rates in the various groups mice. Taken together, these combinatorial approaches of pharmacologic inhibition and gene knockout along with the use of in vitro and intact organ model provide conclusive evidence that activation of A 1 AR plays an essential role in sildenafil-induced protection in the heart. Adenosine is a ubiquitous biological compound formed as a consequence of the breakdown of ATP during ischemic preconditioning. The adenosine receptor system is an intrinsic mechanism which has a role in modifying cell death and injury, inflammatory processes, and cardiac and vascular remodeling during/after ischemic or hypoxic insult and also protect the heart against the injury of I/R and inflammation (reviewed in [20] ). It has been shown that inhibition of A 1 AR activation prevents protection with ischemic preconditioning in rabbits [9] , dogs [21] , and isolated human right atrial trabeculae [22] . Moreover, A 1 AR deletion prevents protection against myocardial infarction in vivo following ischemic preconditioning in mice [23] . Activation of A 1 ARs has been shown to protect the heart from I/ R-induced stunning as well as infarction [24, 25] . Moreover, cardiac-selective A 1 AR overexpression demonstrated enhanced ischemic tolerance as evidenced by the reduction of infarction and improved recovery of contractile function [26] . Conversely, A 1 AR-KO mice were shown to have diminished recovery of left ventricular function compared with WT controls [27] . In the present study, we observed that treatment with sildenafil failed to reduce infarct size in the A 1 AR-KO as compared to the WT controls. These observations were further supported by the ability of DPCPX to block the infarct limiting effect of sildenafil in the WT control hearts. Similar results were obtained when these experiments were reproduced in adult cardiomyocytes subjected to simulated ischemia/reoxygenation. Schulte et al. [28] reported abrogation of the infarct sparing effect of remote (cerebral) ischemic preconditioning in A 1 AR-KO hearts while post-ischemic functional tolerance was not altered by A 1 AR deletion. It is well known that extracellular adenosine acts via four known G-protein-coupled receptor (GPCR) sub-types including A 1 , A 2A , A 2B , and A 3 receptors [30] . Adenosine A 1 and A 3 receptors inhibit adenyl cyclase and stimulate phospholipase C via activation of pertussis toxin sensitive G proteins Gi and/or Go. A 2A and A 2B are positively coupled to adenyl cyclase but also activate alternate signaling pathways [31, 32] . However, it is unlikely that the lack of protective effect of sildenafil in the A 1 AR-KO mice is due to compensatory changes in the expression of other receptor subtypes because A 2A , A 2B , or A 3 receptors were not altered in A 1 AR-KO compared with WT hearts [27] .
Our data raise the intriguing possibility that sildenafil may have caused enhanced expression of A 1 AR on cardiomyocytes, particularly 24 h after treatment. In support of this notion, recent studies have demonstrated that exogenously generated NO as well lipopolysaccharide (LPS) increased A 1 AR expression in pheochromocytoma 12 cells and in primary cultures of cortical neurons [29] . With LPS, the A 1 AR expression was dependent on the induction of inducible nitric oxide synthase (iNOS) because inhibition of NOS activity suppressed this response in these studies. It appears that sildenafil might have worked through NO-dependent increased A 1 AR expression. This is because sildenafil is known to cause a rapid induction of eNOS and iNOS mRNA and a significant increase in cardiac expression of the proteins within 24 h of treatment in the heart [4] . However, considering the shorter duration of action of DPCPX (approximately 5 h) in antagonizing the actions of adenosine [33] , it is not clear how this compound would have been able to block the protective effect of upregulated A 1 AR 24 h later. It is possible that such an action of DPCPX may be indicative of a lack of specificity of action. Alternatively, sildenafil may have caused enhanced release of adenosine through generation of NO which would have activated the A 1 AR receptor and led to subsequent protection from I/R injury 24 h later. Additional studies are needed to address this hypothesis.
In summary, for the first time, we have shown that sildenafil induces delayed cardioprotective effects against myocardial I/R injury through selective activation of A 1 AR. Considering the similarity of action of other PDE-5 inhibitors including Vardenafil and Tadalafil, it is possible that these drugs may also require A 1 AR activation for protecting the heart against I/ R. We therefore propose that the class of PDE-5 inhibitors including sildenafil could be a novel strategy to selectively activate A 1 AR function for the protection of the heart against myocardial infarction following I/R injury and remodeling.
